


This listing of claims will replace all prior versions, and listings, of claims in the application.

**Listing of Claims:**

1. (currently amended) A compound of formula (1):



wherein:

m and n, which may be the same or different, ~~is~~ are each zero or the integer 1 or 2;

Alk<sup>3</sup> is a covalent bond or a straight or branched C<sub>1-6</sub> alkylene chain;

R<sup>1</sup> and R<sup>2</sup>, which may be the same or different, ~~is~~ are each a hydrogen atom or a straight or branched C<sub>1-6</sub> alkyl group;

D is an optionally substituted aromatic or heteroaromatic group;

E is an optionally substituted C<sub>7-10</sub> cycloalkyl, C<sub>7-10</sub> cycloalkenyl or C<sub>7-10</sub> polycycloaliphatic group;

R<sup>a</sup> is an optionally substituted alkyl group;

Y is a pharmaceutically acceptable counter ion;


~~and the salts, solvates, hydrates, tautomers or N-oxides thereof~~

or a salt, solvate, hydrate, tautomer, or N-oxide thereof.

2. (currently amended) A compound according to Claim 1 wherein m and n, which may be the same or different, ~~is~~ are each zero or the integer 1.

3. (currently amended) A compound according to Claim 2 wherein m and n ~~is~~ are each the integer 1.
4. (currently amended) A compound according to ~~any one of Claims 1—3~~ Claim 1 wherein Alk<sup>3</sup> is a -CH<sub>2</sub>-, -CH<sub>2</sub>CH<sub>2</sub>- or -CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>- chain.
5. (original) A compound according to Claim 4 wherein Alk<sup>3</sup> is a -CH<sub>2</sub>- chain.
6. (currently amended) A compound according to ~~any one of Claims 1—5~~ Claim 1 wherein R<sup>1</sup> and R<sup>2</sup>, which may be the same or different, ~~is~~ are each a hydrogen atom or a C<sub>1-3</sub> alkyl group.
7. (currently amended) A compound according to ~~any one of Claims 1—6~~ Claim 1 wherein D is an optionally substituted phenyl, 1- or 2-naphthyl, pyridyl, pyrimidinyl, pyridazinyl, pyrazinyl, benzofuryl, benzothienyl, indolyl, benzimidazolyl, benzothiazolyl, benzoxazolyl, benzisoxazolyl, quinazolinyl, quinoxaliny, naphthyridinyl, quinolinyl, isoquinolinyl, pyrrolyl, furyl, thienyl, imidazolyl, N-C<sub>1-6</sub>alkylimidazolyl, oxazolyl, isoxazolyl, thiazolyl or isothiazolyl group.
8. (currently amended) A compound according to ~~any one of Claims 1—7~~ Claim 1 wherein E is an optionally substituted cycloheptyl, cyclooctyl, cyclononyl, cyclohexenyl, cycloheptenyl, cyclooctenyl, adamantyl, bicyclo[2.2.1]heptanyl, bicyclo[2.2.1]heptenyl, bicyclo[3.1.1]heptanyl or bicyclo[3.1.1]heptenyl group.

9. (original) A compound according to Claim 8 wherein E is a 1-cyclooctenyl or 6,6-dimethylbicyclo[3.1.1]hept-2-en-2-yl, adamantyl or cyclooctyl group.
10. (currently amended) A pharmaceutical composition comprising a compound according to ~~any of Claims 1 to 9~~ Claim 1 together with one or more pharmaceutically acceptable carriers, excipients or diluents.
11. (canceled)
12. (new) A method for treating a disease or disorder involving inappropriate T-cell trafficking comprising administering to a patient suffering from such a disease or disorder a pharmaceutically effective amount of a compound of formula (1):



wherein:

- m and n, which may be the same or different, are each zero or the integer 1 or 2;
- Alk<sup>3</sup> is a covalent bond or a straight or branched C<sub>1-6</sub> alkylene chain;
- R<sup>1</sup> and R<sup>2</sup>, which may be the same or different, are each a hydrogen atom or a straight or branched C<sub>1-6</sub> alkyl group;
- D is an optionally substituted aromatic or heteroaromatic group;
- E is an optionally substituted C<sub>7-10</sub> cycloalkyl, C<sub>7-10</sub> cycloalkenyl or C<sub>7-10</sub> polycycloaliphatic group;

R<sup>a</sup> is an optionally substituted alkyl group;

Y is a pharmaceutically acceptable counter ion;

or a salt, solvate, hydrate, tautomer, or N-oxide thereof.

13. (new) The method of claim 12 wherein the disease or disorder involving inappropriate T-cell trafficking is an inflammatory, autoimmune, or immunoregulatory disease or disorder.

14. (new) The method of claim 13 wherein the inflammatory disease or disorder is systemic anaphylaxis, a drug allergy, an insect sting allergy, inflammatory bowel disease, Crohn's disease, ulcerative colitis, ileitis, enteritis, vaginitis, psoriasis, dermatitis, eczema, atopic dermatitis, allergic contact dermatitis, urticaria, vasculitis, spondyloarthropathies, scleroderma, asthma, allergic rhinitis, or a hypersensitivity lung disease.

15. (new) The method of claim 13 wherein the autoimmune diseases or disorder is rheumatoid arthritis, psoriatic arthritis, multiple sclerosis, systemic lupus erythematosus, diabetes, or glomerulonephritis.

16. (new) The method of claim 12 wherein the disease or disorder is allograft rejection, graft-v-host disease, atherosclerosis, myositis, Alzheimer's disease, encephalitis, meningitis, hepatitis, nephritis, sepsis, sarcoidosis, conjunctivitis, otitis, chronic obstructive pulmonary disease, sinusitis, Behcet's syndrome, Sjorgen's syndrome, or glomerulonephrites